Fast track — ArticlesLiraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Introduction
Type 2 diabetes mellitus is a progressive disease; many treatments work early in the course of disease but do not remain effective.1, 2 Glucagon-like peptide 1 (GLP-1) stimulates glucose-dependent insulin secretion, suppresses glucagon secretion, and moderates appetite by delaying gastric emptying and reducing hunger.3 Endogenous GLP-1 has a very short half-life (1·5 min) because of rapid degradation by dipeptidyl peptidase 4,3 which restricts its therapeutic usefulness. Liraglutide is an analogue of human GLP-1 with 97% homology to the endogenous protein4 and a half life of 13 h, which gives it a pharmacokinetic profile suitable for once daily treatment.5
Liraglutide restores glucose-dependent insulin secretion after one injection in patients with type 2 diabetes mellitus.6 In a 14 week monotherapy trial,7 treatment with liraglutide produced substantial and clinically significant reductions in fasting and postprandial glucose concentrations and glycosylated haemoglobin (HbA1c), resulted in moderate weight loss, and had a very low risk of hypoglycaemia. Common side-effects of liraglutide treatment include gastrointestinal side-effects, such as nausea, diarrhoea, and vomiting.
We investigated the safety and efficacy of two doses of liraglutide versus glimepiride over 52 weeks for treatment of type 2 diabetes mellitus. We studied patients thought to be in the early stages of disease because they were either drug-naive, treated with lifestyle modifications, or had failed to achieve control with a single oral drug at less than 50% of maximum approved dose.
Section snippets
Participants and study design
Participants were aged 18–80 years, had body-mass index of 45 kg/m2 or less, and were diagnosed with type 2 diabetes mellitus. Eligible patients had been treated with diet and exercise (36·5% of patients randomised) or up to half the highest dose of oral antidiabetic drug monotherapy (63·5%) including sulphonylureas, meglitinides, aminoacid derivatives, biguanides, α-glucosidase inhibitors, and thiazolidinediones (1500 mg metformin or 30 mg pioglitazone were allowed) for at least 2 months.
Results
The three treatment groups were well balanced at baseline (figure 1, table 1). In the liraglutide treatment groups, most participants who withdrew did so because of other reasons or adverse events, whereas in the glimepiride group, other or ineffective therapy were the most common reasons for withdrawal. Mean baseline HbA1c and fasting plasma glucose values were 8·2% and 9·5 mmol/L, respectively. Mean baseline weight was 92·6 kg and mean blood pressure was 129/79 mm Hg.
HbA1c values decreased
Discussion
Treatment with liraglutide as monotherapy provided better glycaemic control for 52 weeks than did glimepiride, a traditional first-line secretagogue therapy for type 2 diabetes mellitus, in participants previously treated with either diet and exercise or oral antidiabetic monotherapy. Liraglutide improved glycaemic control with a low rate of hypoglycaemia.
Liraglutide led to decreases in both fasting and postprandial plasma glucose, and its 13 h half-life makes it suitable for once-daily use.
References (21)
- et al.
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
N Engl J Med
(2006) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Lancet
(1998)The physiology of glucagon-like peptide 1
Physiol Rev
(2007)- et al.
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
J Med Chem
(2000) - et al.
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
Diabetologia
(2002) - et al.
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes
Diabetes
(2002) - et al.
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
Diabetes Care
(2007) Declaration of Helsinki: ethical principles for medical research involving human subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assemble, Washington 2002, and Note of Clarification on Paragraph 30 by the WMA General Assembly, Tokyo 2004
ICH Harmonised Tripartite Guideline, Good Clinical Practice
- et al.
Patient reported outcomes in subjects with type 2 diabetes treated with monotherapy regimens of once-daily human GLP-1 analog liraglutide or glimepiride
Diabetologia
(2008)
Cited by (958)
Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond
2024, Metabolism: Clinical and ExperimentalObesity and diabetes
2023, Diabetes Research and Clinical PracticeEffects of GLP-1 Agonists on mortality and arrhythmias in patients with Type II diabetes
2023, IJC Heart and VasculatureIs the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
2023, European Journal of Internal Medicine
- ‡
Members listed at end of paper